Brind.

Madrigal Pharmaceuticals is focusing on novel therapeutics for MASH and has secured a $500 million credit facility.

2 reports, 2 independent Updated Jul 1
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Madrigal Pharmaceuticals is focusing on novel therapeutics for MASH and has secured a $500 million credit facility.

Who's involved

What this event is mainly about
Madrigal Pharmaceuticals (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. Joint MASH program accelerates drug development.1 source
  2. Madrigal secured $500M credit facility for novel MASH therapeutics.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • GlobeNewswireMadrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH Proceeds to primarily support MASH pipeline expansion